ID   MRC2_HUMAN              Reviewed;        1479 AA.
AC   Q9UBG0; A6H8K4; D3DU08; Q7LGE7; Q9Y5P9;
DT   07-FEB-2006, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 2.
DT   03-AUG-2022, entry version 165.
DE   RecName: Full=C-type mannose receptor 2;
DE   AltName: Full=C-type lectin domain family 13 member E;
DE   AltName: Full=Endocytic receptor 180;
DE   AltName: Full=Macrophage mannose receptor 2;
DE   AltName: Full=Urokinase-type plasminogen activator receptor-associated protein;
DE            Short=UPAR-associated protein;
DE            Short=Urokinase receptor-associated protein;
DE   AltName: CD_antigen=CD280;
DE   Flags: Precursor;
GN   Name=MRC2; Synonyms=CLEC13E, ENDO180, KIAA0709, UPARAP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 350-360, IDENTIFICATION BY
RP   MASS SPECTROMETRY, SUBUNIT, AND VARIANT HIS-1156.
RX   PubMed=10636902; DOI=10.1074/jbc.275.3.1993;
RA   Behrendt N., Jensen O.N., Engelholm L.H., Moertz E., Mann M., Danoe K.;
RT   "A urokinase receptor-associated protein with specific collagen binding
RT   properties.";
RL   J. Biol. Chem. 275:1993-2002(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, PHOSPHORYLATION, GLYCOSYLATION,
RP   TISSUE SPECIFICITY, AND VARIANTS ILE-43 AND HIS-1156.
RX   PubMed=10683150; DOI=10.1242/jcs.113.6.1021;
RA   Sheikh H., Yarwood H., Ashworth A., Isacke C.M.;
RT   "Endo180, an endocytic recycling glycoprotein related to the macrophage
RT   mannose receptor is expressed on fibroblasts, endothelial cells and
RT   macrophages and functions as a lectin receptor.";
RL   J. Cell Sci. 113:1021-1032(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT HIS-1156.
RC   TISSUE=Brain;
RX   PubMed=9734811; DOI=10.1093/dnares/5.3.169;
RA   Ishikawa K., Nagase T., Suyama M., Miyajima N., Tanaka A., Kotani H.,
RA   Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. X. The
RT   complete sequences of 100 new cDNA clones from brain which can code for
RT   large proteins in vitro.";
RL   DNA Res. 5:169-176(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT HIS-1156.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT HIS-1156.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=8702911; DOI=10.1074/jbc.271.35.21323;
RA   Wu K., Yuan J., Lasky L.A.;
RT   "Characterization of a novel member of the macrophage mannose receptor type
RT   C lectin family.";
RL   J. Biol. Chem. 271:21323-21330(1996).
RN   [8]
RP   MUTAGENESIS OF TYR-1452; GLU-1464 AND 1468-LEU-VAL-1469.
RX   PubMed=12068012; DOI=10.1074/jbc.m203631200;
RA   Howard M.J., Isacke C.M.;
RT   "The C-type lectin receptor Endo180 displays internalization and recycling
RT   properties distinct from other members of the mannose receptor family.";
RL   J. Biol. Chem. 277:32320-32331(2002).
RN   [9]
RP   DOMAIN, AND MUTAGENESIS OF ASN-472.
RX   PubMed=12399458; DOI=10.1074/jbc.m208985200;
RA   East L., Rushton S., Taylor M.E., Isacke C.M.;
RT   "Characterization of sugar binding by the mannose receptor family member,
RT   Endo180.";
RL   J. Biol. Chem. 277:50469-50475(2002).
RN   [10]
RP   FUNCTION, AND DOMAIN.
RX   PubMed=12972549; DOI=10.1091/mbc.e02-12-0814;
RA   Wienke D., MacFadyen J.R., Isacke C.M.;
RT   "Identification and characterization of the endocytic transmembrane
RT   glycoprotein Endo180 as a novel collagen receptor.";
RL   Mol. Biol. Cell 14:3592-3604(2003).
RN   [11]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-69.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [12]
RP   GLYCOSYLATION AT ASN-69.
RX   PubMed=19139490; DOI=10.1074/mcp.m800504-mcp200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F., Zheng Z.B.,
RA   Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y., Zhang Y.K., Deng Y.L.,
RA   Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core fucosylated
RT   glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [13]
RP   SUMOYLATION AT LYS-1142.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20388717; DOI=10.1074/jbc.m110.106955;
RA   Blomster H.A., Imanishi S.Y., Siimes J., Kastu J., Morrice N.A.,
RA   Eriksson J.E., Sistonen L.;
RT   "In vivo identification of sumoylation sites by a signature tag and
RT   cysteine-targeted affinity purification.";
RL   J. Biol. Chem. 285:19324-19329(2010).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
CC   -!- FUNCTION: May play a role as endocytotic lectin receptor displaying
CC       calcium-dependent lectin activity. Internalizes glycosylated ligands
CC       from the extracellular space for release in an endosomal compartment
CC       via clathrin-mediated endocytosis. May be involved in plasminogen
CC       activation system controlling the extracellular level of PLAUR/PLAU,
CC       and thus may regulate protease activity at the cell surface. May
CC       contribute to cellular uptake, remodeling and degradation of
CC       extracellular collagen matrices. May play a role during cancer
CC       progression as well as in other chronic tissue destructive diseases
CC       acting on collagen turnover. May participate in remodeling of
CC       extracellular matrix cooperating with the matrix metalloproteinases
CC       (MMPs). {ECO:0000269|PubMed:10683150, ECO:0000269|PubMed:12972549}.
CC   -!- SUBUNIT: Interacts with C-terminal region of type I collagen/COL1A1 (By
CC       similarity). Interacts directly with PLAUR/UPAR and PLAU/pro-UPA to
CC       form a tri-molecular complex. Interacts with collagen V. {ECO:0000250,
CC       ECO:0000269|PubMed:10636902}.
CC   -!- INTERACTION:
CC       Q9UBG0; P02454: Col1a1; Xeno; NbExp=2; IntAct=EBI-1104992, EBI-915744;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein.
CC   -!- TISSUE SPECIFICITY: Ubiquitous with low expression in brain, placenta,
CC       lung, kidney, pancreas, spleen, thymus and colon. Expressed in
CC       endothelial cells, fibroblasts and macrophages. Highly expressed in
CC       fetal lung and kidney. {ECO:0000269|PubMed:10683150,
CC       ECO:0000269|PubMed:8702911}.
CC   -!- DOMAIN: C-type lectin domains 3 to 8 are not required for calcium-
CC       dependent binding of mannose, fucose and N-acetylglucosamine. C-type
CC       lectin domain 2 is responsible for sugar-binding in a calcium-dependent
CC       manner.
CC   -!- DOMAIN: Fibronectin type-II domain mediates collagen-binding.
CC   -!- DOMAIN: Ricin B-type lectin domain contacts with the second C-type
CC       lectin domain. {ECO:0000250}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:10683150,
CC       ECO:0000269|PubMed:19139490, ECO:0000269|PubMed:19159218}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA31684.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Functional Glycomics Gateway - Glycan Binding;
CC       Note=Endo180;
CC       URL="http://www.functionalglycomics.org/glycomics/GBPServlet?&operationType=view&cbpId=cbp_hum_Ctlect_251";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF107292; AAF14192.1; -; mRNA.
DR   EMBL; AF134838; AAD30280.1; -; mRNA.
DR   EMBL; AB014609; BAA31684.2; ALT_INIT; mRNA.
DR   EMBL; AC080038; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471109; EAW94341.1; -; Genomic_DNA.
DR   EMBL; CH471109; EAW94342.1; -; Genomic_DNA.
DR   EMBL; BC146647; AAI46648.1; -; mRNA.
DR   EMBL; BC150212; AAI50213.1; -; mRNA.
DR   EMBL; BC153884; AAI53885.1; -; mRNA.
DR   CCDS; CCDS11634.1; -.
DR   RefSeq; NP_006030.2; NM_006039.4.
DR   PDB; 5AO5; X-ray; 2.48 A; A/B=35-511.
DR   PDB; 5AO6; X-ray; 3.36 A; A/B=35-511.
DR   PDB; 5E4K; X-ray; 2.58 A; A=31-510.
DR   PDB; 5E4L; X-ray; 2.44 A; A/B=31-510.
DR   PDB; 5EW6; X-ray; 2.29 A; A=31-510.
DR   PDBsum; 5AO5; -.
DR   PDBsum; 5AO6; -.
DR   PDBsum; 5E4K; -.
DR   PDBsum; 5E4L; -.
DR   PDBsum; 5EW6; -.
DR   AlphaFoldDB; Q9UBG0; -.
DR   SMR; Q9UBG0; -.
DR   BioGRID; 115231; 68.
DR   DIP; DIP-37631N; -.
DR   IntAct; Q9UBG0; 35.
DR   MINT; Q9UBG0; -.
DR   STRING; 9606.ENSP00000307513; -.
DR   GlyConnect; 764; 17 N-Linked glycans (5 sites).
DR   GlyGen; Q9UBG0; 10 sites, 16 N-linked glycans (5 sites).
DR   iPTMnet; Q9UBG0; -.
DR   PhosphoSitePlus; Q9UBG0; -.
DR   SwissPalm; Q9UBG0; -.
DR   BioMuta; MRC2; -.
DR   DMDM; 317373394; -.
DR   EPD; Q9UBG0; -.
DR   jPOST; Q9UBG0; -.
DR   MassIVE; Q9UBG0; -.
DR   MaxQB; Q9UBG0; -.
DR   PaxDb; Q9UBG0; -.
DR   PeptideAtlas; Q9UBG0; -.
DR   PRIDE; Q9UBG0; -.
DR   ProteomicsDB; 83964; -.
DR   Antibodypedia; 31250; 261 antibodies from 30 providers.
DR   DNASU; 9902; -.
DR   Ensembl; ENST00000303375.10; ENSP00000307513.5; ENSG00000011028.14.
DR   GeneID; 9902; -.
DR   KEGG; hsa:9902; -.
DR   MANE-Select; ENST00000303375.10; ENSP00000307513.5; NM_006039.5; NP_006030.2.
DR   UCSC; uc002jad.5; human.
DR   CTD; 9902; -.
DR   DisGeNET; 9902; -.
DR   GeneCards; MRC2; -.
DR   HGNC; HGNC:16875; MRC2.
DR   HPA; ENSG00000011028; Low tissue specificity.
DR   MIM; 612264; gene.
DR   neXtProt; NX_Q9UBG0; -.
DR   OpenTargets; ENSG00000011028; -.
DR   PharmGKB; PA134988161; -.
DR   VEuPathDB; HostDB:ENSG00000011028; -.
DR   eggNOG; KOG4297; Eukaryota.
DR   GeneTree; ENSGT01050000244842; -.
DR   HOGENOM; CLU_002069_2_0_1; -.
DR   InParanoid; Q9UBG0; -.
DR   OMA; GFIWEHI; -.
DR   OrthoDB; 29241at2759; -.
DR   PhylomeDB; Q9UBG0; -.
DR   TreeFam; TF316663; -.
DR   PathwayCommons; Q9UBG0; -.
DR   Reactome; R-HSA-1236978; Cross-presentation of soluble exogenous antigens (endosomes).
DR   SignaLink; Q9UBG0; -.
DR   BioGRID-ORCS; 9902; 15 hits in 1076 CRISPR screens.
DR   ChiTaRS; MRC2; human.
DR   GenomeRNAi; 9902; -.
DR   Pharos; Q9UBG0; Tbio.
DR   PRO; PR:Q9UBG0; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q9UBG0; protein.
DR   Bgee; ENSG00000011028; Expressed in tendon of biceps brachii and 207 other tissues.
DR   ExpressionAtlas; Q9UBG0; baseline and differential.
DR   Genevisible; Q9UBG0; HS.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW.
DR   GO; GO:0005518; F:collagen binding; IDA:UniProtKB.
DR   GO; GO:0038023; F:signaling receptor activity; IBA:GO_Central.
DR   GO; GO:0030574; P:collagen catabolic process; IDA:UniProtKB.
DR   GO; GO:0006897; P:endocytosis; IEA:UniProtKB-KW.
DR   GO; GO:0001649; P:osteoblast differentiation; HDA:UniProtKB.
DR   CDD; cd03590; CLECT_DC-SIGN_like; 1.
DR   CDD; cd00062; FN2; 1.
DR   CDD; cd00161; RICIN; 1.
DR   Gene3D; 2.10.10.10; -; 1.
DR   Gene3D; 3.10.100.10; -; 8.
DR   InterPro; IPR001304; C-type_lectin-like.
DR   InterPro; IPR016186; C-type_lectin-like/link_sf.
DR   InterPro; IPR018378; C-type_lectin_CS.
DR   InterPro; IPR033989; CD209-like_CTLD.
DR   InterPro; IPR016187; CTDL_fold.
DR   InterPro; IPR000562; FN_type2_dom.
DR   InterPro; IPR036943; FN_type2_sf.
DR   InterPro; IPR013806; Kringle-like.
DR   InterPro; IPR035992; Ricin_B-like_lectins.
DR   InterPro; IPR000772; Ricin_B_lectin.
DR   Pfam; PF00040; fn2; 1.
DR   Pfam; PF00059; Lectin_C; 8.
DR   SMART; SM00034; CLECT; 8.
DR   SMART; SM00059; FN2; 1.
DR   SMART; SM00458; RICIN; 1.
DR   SUPFAM; SSF50370; SSF50370; 1.
DR   SUPFAM; SSF56436; SSF56436; 8.
DR   SUPFAM; SSF57440; SSF57440; 1.
DR   PROSITE; PS00615; C_TYPE_LECTIN_1; 3.
DR   PROSITE; PS50041; C_TYPE_LECTIN_2; 8.
DR   PROSITE; PS00023; FN2_1; 1.
DR   PROSITE; PS51092; FN2_2; 1.
DR   PROSITE; PS50231; RICIN_B_LECTIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Direct protein sequencing; Disulfide bond;
KW   Endocytosis; Glycoprotein; Isopeptide bond; Lectin; Membrane;
KW   Phosphoprotein; Receptor; Reference proteome; Repeat; Signal;
KW   Transmembrane; Transmembrane helix; Ubl conjugation.
FT   SIGNAL          1..30
FT                   /evidence="ECO:0000255"
FT   CHAIN           31..1479
FT                   /note="C-type mannose receptor 2"
FT                   /id="PRO_0000046078"
FT   TOPO_DOM        31..1414
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1415..1435
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1436..1479
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          41..167
FT                   /note="Ricin B-type lectin"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174"
FT   DOMAIN          182..230
FT                   /note="Fibronectin type-II"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00479"
FT   DOMAIN          244..360
FT                   /note="C-type lectin 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   DOMAIN          389..505
FT                   /note="C-type lectin 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   DOMAIN          528..644
FT                   /note="C-type lectin 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   DOMAIN          678..809
FT                   /note="C-type lectin 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   DOMAIN          832..951
FT                   /note="C-type lectin 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   DOMAIN          979..1107
FT                   /note="C-type lectin 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   DOMAIN          1132..1243
FT                   /note="C-type lectin 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   DOMAIN          1273..1393
FT                   /note="C-type lectin 8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00040"
FT   REGION          1450..1479
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1451..1479
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   CARBOHYD        69
FT                   /note="N-linked (GlcNAc...) (complex) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19139490,
FT                   ECO:0000269|PubMed:19159218"
FT   CARBOHYD        140
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        364
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        588
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        954
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1029
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1350
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        54..68
FT                   /evidence="ECO:0000250"
FT   DISULFID        93..112
FT                   /evidence="ECO:0000250"
FT   DISULFID        187..213
FT                   /evidence="ECO:0000250"
FT   DISULFID        201..228
FT                   /evidence="ECO:0000250"
FT   DISULFID        266..359
FT                   /evidence="ECO:0000250"
FT   DISULFID        335..351
FT                   /evidence="ECO:0000250"
FT   DISULFID        410..504
FT                   /evidence="ECO:0000250"
FT   DISULFID        481..496
FT                   /evidence="ECO:0000250"
FT   DISULFID        618..635
FT                   /evidence="ECO:0000250"
FT   DISULFID        704..808
FT                   /evidence="ECO:0000250"
FT   DISULFID        785..800
FT                   /evidence="ECO:0000250"
FT   DISULFID        853..950
FT                   /evidence="ECO:0000250"
FT   DISULFID        927..942
FT                   /evidence="ECO:0000250"
FT   DISULFID        1078..1098
FT                   /evidence="ECO:0000250"
FT   DISULFID        1220..1234
FT                   /evidence="ECO:0000250"
FT   DISULFID        1369..1384
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        1142
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1)"
FT   VARIANT         43
FT                   /note="V -> I (in dbSNP:rs2014055)"
FT                   /evidence="ECO:0000269|PubMed:10683150"
FT                   /id="VAR_025304"
FT   VARIANT         1156
FT                   /note="R -> H (in dbSNP:rs2429387)"
FT                   /evidence="ECO:0000269|PubMed:10636902,
FT                   ECO:0000269|PubMed:10683150, ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:9734811, ECO:0000269|Ref.5"
FT                   /id="VAR_025305"
FT   MUTAGEN         472
FT                   /note="N->D: Reduced sugar-binding activity."
FT                   /evidence="ECO:0000269|PubMed:12399458"
FT   MUTAGEN         1452
FT                   /note="Y->A: No alteration of distribution and
FT                   trafficking."
FT                   /evidence="ECO:0000269|PubMed:12068012"
FT   MUTAGEN         1464
FT                   /note="E->A: Increased cell surface distribution."
FT                   /evidence="ECO:0000269|PubMed:12068012"
FT   MUTAGEN         1468..1469
FT                   /note="LV->AA: Reduction of endocytotic activity;
FT                   distribution almost restricted to the cell surface."
FT                   /evidence="ECO:0000269|PubMed:12068012"
FT   STRAND          46..48
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   TURN            49..52
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          53..58
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          61..67
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   HELIX           73..75
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          77..80
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   TURN            81..83
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          84..87
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   TURN            88..91
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          92..96
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          108..110
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          116..118
FT                   /evidence="ECO:0007829|PDB:5AO5"
FT   TURN            123..125
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   HELIX           126..134
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   HELIX           138..141
FT                   /evidence="ECO:0007829|PDB:5E4L"
FT   STRAND          158..160
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   TURN            161..163
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   TURN            180..184
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          189..193
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          196..200
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          212..218
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   HELIX           219..222
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          225..227
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   TURN            236..238
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          240..242
FT                   /evidence="ECO:0007829|PDB:5AO5"
FT   TURN            243..245
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          248..257
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   HELIX           259..267
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   TURN            268..270
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   HELIX           279..288
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   TURN            289..291
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          295..301
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          303..305
FT                   /evidence="ECO:0007829|PDB:5AO5"
FT   STRAND          309..311
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          330..332
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          335..339
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   TURN            340..343
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          344..349
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          355..361
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          387..389
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          392..401
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   HELIX           403..412
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   HELIX           423..432
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   TURN            433..436
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          439..445
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          447..449
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          452..455
FT                   /evidence="ECO:0007829|PDB:5E4L"
FT   TURN            474..476
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          478..485
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   TURN            486..489
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          490..495
FT                   /evidence="ECO:0007829|PDB:5EW6"
FT   STRAND          500..507
FT                   /evidence="ECO:0007829|PDB:5EW6"
SQ   SEQUENCE   1479 AA;  166674 MW;  AAAA5286F91DF7E7 CRC64;
     MGPGRPAPAP WPRHLLRCVL LLGCLHLGRP GAPGDAALPE PNVFLIFSHG LQGCLEAQGG
     QVRVTPACNT SLPAQRWKWV SRNRLFNLGT MQCLGTGWPG TNTTASLGMY ECDREALNLR
     WHCRTLGDQL SLLLGARTSN ISKPGTLERG DQTRSGQWRI YGSEEDLCAL PYHEVYTIQG
     NSHGKPCTIP FKYDNQWFHG CTSTGREDGH LWCATTQDYG KDERWGFCPI KSNDCETFWD
     KDQLTDSCYQ FNFQSTLSWR EAWASCEQQG ADLLSITEIH EQTYINGLLT GYSSTLWIGL
     NDLDTSGGWQ WSDNSPLKYL NWESDQPDNP SEENCGVIRT ESSGGWQNRD CSIALPYVCK
     KKPNATAEPT PPDRWANVKV ECEPSWQPFQ GHCYRLQAEK RSWQESKKAC LRGGGDLVSI
     HSMAELEFIT KQIKQEVEEL WIGLNDLKLQ MNFEWSDGSL VSFTHWHPFE PNNFRDSLED
     CVTIWGPEGR WNDSPCNQSL PSICKKAGQL SQGAAEEDHG CRKGWTWHSP SCYWLGEDQV
     TYSEARRLCT DHGSQLVTIT NRFEQAFVSS LIYNWEGEYF WTALQDLNST GSFFWLSGDE
     VMYTHWNRDQ PGYSRGGCVA LATGSAMGLW EVKNCTSFRA RYICRQSLGT PVTPELPGPD
     PTPSLTGSCP QGWASDTKLR YCYKVFSSER LQDKKSWVQA QGACQELGAQ LLSLASYEEE
     HFVANMLNKI FGESEPEIHE QHWFWIGLNR RDPRGGQSWR WSDGVGFSYH NFDRSRHDDD
     DIRGCAVLDL ASLQWVAMQC DTQLDWICKI PRGTDVREPD DSPQGRREWL RFQEAEYKFF
     EHHSTWAQAQ RICTWFQAEL TSVHSQAELD FLSHNLQKFS RAQEQHWWIG LHTSESDGRF
     RWTDGSIINF ISWAPGKPRP VGKDKKCVYM TASREDWGDQ RCLTALPYIC KRSNVTKETQ
     PPDLPTTALG GCPSDWIQFL NKCFQVQGQE PQSRVKWSEA QFSCEQQEAQ LVTITNPLEQ
     AFITASLPNV TFDLWIGLHA SQRDFQWVEQ EPLMYANWAP GEPSGPSPAP SGNKPTSCAV
     VLHSPSAHFT GRWDDRSCTE ETHGFICQKG TDPSLSPSPA ALPPAPGTEL SYLNGTFRLL
     QKPLRWHDAL LLCESRNASL AYVPDPYTQA FLTQAARGLR TPLWIGLAGE EGSRRYSWVS
     EEPLNYVGWQ DGEPQQPGGC TYVDVDGAWR TTSCDTKLQG AVCGVSSGPP PPRRISYHGS
     CPQGLADSAW IPFREHCYSF HMELLLGHKE ARQRCQRAGG AVLSILDEME NVFVWEHLQS
     YEGQSRGAWL GMNFNPKGGT LVWQDNTAVN YSNWGPPGLG PSMLSHNSCY WIQSNSGLWR
     PGACTNITMG VVCKLPRAEQ SSFSPSALPE NPAALVVVLM AVLLLLALLT AALILYRRRQ
     SIERGAFEGA RYSRSSSSPT EATEKNILVS DMEMNEQQE
//
